Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA reported that Chief Medical Officer Philippe Menu executed a sale of 5,000 Ordinary Shares on 2026-07-27. The shares were sold at a weighted average price of $5.6611 per share, with individual trades occurring between $5.57 and $5.83. The sale was carried out under a duly adopted Rule 10b5-1(c) trading plan, indicating it was pre-arranged. After this transaction, Menu directly holds 223,387 Ordinary Shares of SOPHiA GENETICS SA.
SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. On July 20, 2026, he exercised options for 4,581 ordinary shares at $3.16 per share and sold 4,581 shares at a weighted average $6.1654, in multiple trades between $6.10 and $6.20, plus 19,800 shares at a weighted average $6.3233, in trades between $6.30 and $6.37. On July 21, 2026, he sold 20,000 ordinary shares at a weighted average $6.6327, in trades between $6.60 and $6.72. A footnote states he continues to hold 4,641,476 derivative share options across remaining grant tranches.
SOPHiA GENETICS reports that an affiliate, acting through Morgan Stanley Smith Barney LLC Executive Financial Services, has filed to sell up to 37,000 shares of common stock classified as founders shares. The proposed sale amount is listed at $234,210.00.
The filing also details prior sales under a Rule 10b5-1 trading plan for Jurgi Camblong, including 65,269 common shares sold on June 30, 2026 for $398,632.27 and 50,069 shares sold on June 26, 2026 for $290,329.01, along with several smaller transactions between May and July 2026.
The filing for SOPH reports a planned sale of common stock by insider Jurgi Camblong. The notice lists 4,581 common shares to be sold following an exercise of stock options dated July 20, 2026, and an additional 19,800 founder shares dated March 18, 2021.
The sales are arranged through Morgan Stanley Smith Barney LLC Executive Financial Services and reference prior activity under a Rule 10b5-1 trading plan. Recent plan sales include 65,269 shares for $398,632.27 on June 30, 2026 and 50,069 shares for $290,329.01 on June 26, 2026, alongside multiple smaller transactions in May, June, and July 2026.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu completed an open-market sale of 5,000 Ordinary Shares on 2026-07-13 at a weighted average price of $5.701 per share, with individual trade prices between $5.55 and $5.79, pursuant to a duly adopted Rule 10b5-1(c) trading plan. Following the transaction, he directly holds 228,387 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu completed an open-market sale of 4,000 Ordinary Shares on July 13, 2026, at a weighted average price of $5.7048 per share. The transaction was made under a duly adopted Rule 10b5-1(c) trading plan, and Xu now directly holds 610,887 Ordinary Shares.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 8,500 Ordinary Shares on July 10, 2026 at a weighted average price of $5.6225 per share. The transaction was made pursuant to a Rule 10b5-1(c) trading plan, and he continues to hold 3,532,622 shares directly. The shares were sold in multiple trades at prices between $5.53 and $5.77.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported an open-market sale of 17,685 Ordinary Shares at an average price of $5.2772 per share. According to the filing, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on July 3, 2026, under a pre-established Rule 10b5-1(c) trading plan. After this transaction, Camblong directly holds 3,541,122 Ordinary Shares, indicating the sale is small relative to his remaining stake and was executed on a non-discretionary basis.
SOPH reported Rule 144/Form 144 sale activity by a holder under a pre-arranged 10b5-1 plan, reporting multiple open-market dispositions of Common shares. The filings list individual 10b5-1 sales across multiple dates in 2026, including trades of 65,269 shares on 06/30/2026 and 50,069 shares on 06/26/2026. The record also shows holdings from Restricted Stock Units and Founders Shares with grant dates of 07/02/2026 and 03/18/2021, respectively.
SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction. The weighted average sale price was $5.2886 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on July 2, 2026 and was executed under a pre‑established Rule 10b5‑1(c) trading plan. After this tax‑related sale, Cardoza directly holds 309,092 Ordinary Shares.